KR101770531B1 - 타우-펫-리간드로서의 다이아자카르바졸 유도체 - Google Patents

타우-펫-리간드로서의 다이아자카르바졸 유도체 Download PDF

Info

Publication number
KR101770531B1
KR101770531B1 KR1020167008013A KR20167008013A KR101770531B1 KR 101770531 B1 KR101770531 B1 KR 101770531B1 KR 1020167008013 A KR1020167008013 A KR 1020167008013A KR 20167008013 A KR20167008013 A KR 20167008013A KR 101770531 B1 KR101770531 B1 KR 101770531B1
Authority
KR
South Korea
Prior art keywords
formula
compound
tau
fluoro
rti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167008013A
Other languages
English (en)
Korean (ko)
Other versions
KR20160047552A (ko
Inventor
루카 고비
헨너 크너스트
마티아스 쾨르너
디터 무리
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20160047552A publication Critical patent/KR20160047552A/ko
Application granted granted Critical
Publication of KR101770531B1 publication Critical patent/KR101770531B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020167008013A 2013-10-08 2014-10-06 타우-펫-리간드로서의 다이아자카르바졸 유도체 Active KR101770531B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13187764.9 2013-10-08
EP13187764 2013-10-08
PCT/EP2014/071283 WO2015052105A1 (en) 2013-10-08 2014-10-06 Diazacarbazole derivatives as tau-pet-ligands

Publications (2)

Publication Number Publication Date
KR20160047552A KR20160047552A (ko) 2016-05-02
KR101770531B1 true KR101770531B1 (ko) 2017-08-22

Family

ID=49301396

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167008013A Active KR101770531B1 (ko) 2013-10-08 2014-10-06 타우-펫-리간드로서의 다이아자카르바졸 유도체

Country Status (32)

Country Link
US (2) US10004817B2 (enExample)
EP (1) EP3055308B1 (enExample)
JP (1) JP6194416B2 (enExample)
KR (1) KR101770531B1 (enExample)
CN (1) CN105358558B (enExample)
AR (1) AR097931A1 (enExample)
AU (1) AU2014333996B2 (enExample)
CA (1) CA2917191C (enExample)
CL (1) CL2016000728A1 (enExample)
CR (1) CR20150663A (enExample)
DK (1) DK3055308T3 (enExample)
EA (1) EA028483B1 (enExample)
ES (1) ES2657121T3 (enExample)
HR (1) HRP20180049T1 (enExample)
HU (1) HUE035413T2 (enExample)
IL (1) IL243249A0 (enExample)
LT (1) LT3055308T (enExample)
MA (1) MA38935B1 (enExample)
MX (1) MX373153B (enExample)
MY (1) MY190196A (enExample)
NO (1) NO3055308T3 (enExample)
PE (1) PE20160159A1 (enExample)
PH (1) PH12016500249B1 (enExample)
PL (1) PL3055308T3 (enExample)
PT (1) PT3055308T (enExample)
RS (1) RS56777B1 (enExample)
SG (1) SG11201602786UA (enExample)
SI (1) SI3055308T1 (enExample)
TW (1) TWI513698B (enExample)
UA (1) UA116164C2 (enExample)
WO (1) WO2015052105A1 (enExample)
ZA (1) ZA201509013B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100135235A (ko) 2008-02-14 2010-12-24 지멘스 메디컬 솔루션즈 유에스에이, 인크. 신경학적 기능이상을 검출하기 위한 조영제
NO3055308T3 (enExample) 2013-10-08 2018-04-21
PT3143011T (pt) 2014-05-13 2021-04-26 Hoffmann La Roche Compostos heterocíclicos deuterados e a sua utilização como agentes de imagiologia
ES2875734T3 (es) 2015-02-02 2021-11-11 UCB Biopharma SRL Derivados de 9H-pirrolo-dipiridina
EP3118202A1 (en) 2015-07-15 2017-01-18 AC Immune S.A. Dihydropyridopyrrole derivatives as tau-pet-ligands
WO2017009454A1 (en) 2015-07-15 2017-01-19 Ac Immune S.A. Novel imaging compounds
MX386900B (es) 2016-07-22 2025-03-19 Ac Immune S A Star Compuestos para formacion de imagenes de agregados de proteinas tau.
WO2018015546A1 (en) 2016-07-22 2018-01-25 Ac Immune S.A. Compounds for imaging tau protein aggregates
WO2018024643A1 (en) 2016-08-02 2018-02-08 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
WO2018024642A1 (en) 2016-08-02 2018-02-08 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
MX375720B (es) 2016-09-09 2025-03-04 Hoffmann La Roche Proceso para preparacion de 2-(6-nitropiridin-3-il)-9h-dipirido[2,3-beta;3',4'-d]pirrol.
JP7260552B2 (ja) * 2018-01-24 2023-04-18 エーシー・イミューン・エス・アー Ｐｅｔ画像化のための診断用組成物、診断用組成物を製造するための方法及び診断におけるその使用
KR20200113234A (ko) 2018-01-24 2020-10-06 에이씨 이뮨 에스.에이. 이미징 화합물을 제조하는 신규한 방법
EP3743423A1 (en) 2018-01-24 2020-12-02 AC Immune SA Gamma-carboline compounds for the detection of tau aggregates
EP3743426A1 (en) 2018-01-24 2020-12-02 AC Immune SA Azacarboline compounds for the detection of tau aggregates

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009102498A1 (en) 2008-02-14 2009-08-20 Siemens Medical Solutions Usa, Inc. Novel imaging agents for detecting neurological dysfunction
US20110182812A1 (en) 2009-03-23 2011-07-28 Siemens Medical Solutions Usa, Inc. Imaging Agents for Detecting Neurological Disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932557B2 (en) * 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
BRPI0909957A2 (pt) 2008-06-11 2016-04-19 Genentech Inc "composto, composição farmacêutica, método de inibir o crescimento anormal de células ou de tratar um distúrbio hiperproliferativo em um mamífero, método de tratamento do câncer em um mamífero"
US8420052B2 (en) * 2008-07-24 2013-04-16 Siemens Medical Solutions Usa, Inc. Imaging agents useful for identifying AD pathology
CN102438660A (zh) * 2009-03-23 2012-05-02 美国西门子医疗解决公司 用于检测神经障碍的显像剂
US20110183938A1 (en) 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
US20150368244A1 (en) * 2011-01-31 2015-12-24 Genentech, Inc. Diazacarbazoles and methods of use
NO3055308T3 (enExample) * 2013-10-08 2018-04-21

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009102498A1 (en) 2008-02-14 2009-08-20 Siemens Medical Solutions Usa, Inc. Novel imaging agents for detecting neurological dysfunction
US20110182812A1 (en) 2009-03-23 2011-07-28 Siemens Medical Solutions Usa, Inc. Imaging Agents for Detecting Neurological Disorders

Also Published As

Publication number Publication date
DK3055308T3 (en) 2018-01-22
MA38935A1 (fr) 2016-04-29
PL3055308T3 (pl) 2018-03-30
US20180326099A1 (en) 2018-11-15
PE20160159A1 (es) 2016-03-18
US10004817B2 (en) 2018-06-26
CA2917191A1 (en) 2015-04-16
AR097931A1 (es) 2016-04-20
CL2016000728A1 (es) 2016-11-11
AU2014333996B2 (en) 2018-03-15
KR20160047552A (ko) 2016-05-02
HUE035413T2 (en) 2018-05-02
HRP20180049T1 (hr) 2018-02-09
NO3055308T3 (enExample) 2018-04-21
ES2657121T3 (es) 2018-03-01
LT3055308T (lt) 2018-02-12
EP3055308A1 (en) 2016-08-17
IL243249A0 (en) 2016-02-29
TWI513698B (zh) 2015-12-21
CA2917191C (en) 2021-08-10
MX2016002234A (es) 2016-06-06
PT3055308T (pt) 2018-01-18
MY190196A (en) 2022-04-04
EA028483B1 (ru) 2017-11-30
HK1215574A1 (zh) 2016-09-02
JP6194416B2 (ja) 2017-09-06
UA116164C2 (uk) 2018-02-12
EA201690515A1 (ru) 2016-07-29
JP2016534979A (ja) 2016-11-10
PH12016500249A1 (en) 2016-05-16
US11058781B2 (en) 2021-07-13
CR20150663A (es) 2016-01-27
MX373153B (es) 2020-04-21
TW201520212A (zh) 2015-06-01
CN105358558B (zh) 2017-09-26
US20160220712A1 (en) 2016-08-04
CN105358558A (zh) 2016-02-24
ZA201509013B (en) 2016-10-26
EP3055308B1 (en) 2017-11-22
WO2015052105A1 (en) 2015-04-16
MA38935B1 (fr) 2016-12-30
SI3055308T1 (en) 2018-03-30
NZ714831A (en) 2021-09-24
RS56777B1 (sr) 2018-04-30
SG11201602786UA (en) 2016-05-30
PH12016500249B1 (en) 2016-05-16
AU2014333996A1 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
KR101770531B1 (ko) 타우-펫-리간드로서의 다이아자카르바졸 유도체
KR101770532B1 (ko) 이미징 수단으로서의 이미다조[1,2-a]피리딘-7-아민
CN111868062B (zh) 制备显像化合物的方法
HK1215574B (en) Diazacarbazole derivatives as tau-pet-ligands
NZ714831B2 (en) Diazacarbazole derivatives as tau-pet-ligands
BR112016000622B1 (pt) Derivados de diazacarbazol como ligantes de tau-pet, seu processo de fabricação e preparação farmacêutica
EP4658651A1 (en) Novel compounds for tau imaging
JP2026504445A (ja) タウイメージングのための新規化合物
HK1220201B (en) Imidazo[1,2-a]pyridin-7-amines as imaging tools

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 9